Medical Care
Global RNAi for Therapeutic Market Research Report 2025
- May 05, 25
- ID: 229113
- Pages: 81
- Figures: 90
- Views: 9
The global market for RNAi for Therapeutic was valued at US$ 358 million in the year 2024 and is projected to reach a revised size of US$ 4272 million by 2031, growing at a CAGR of 43.1% during the forecast period.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global RNAi for Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi for Therapeutic Market Perspective (2020-2031)
2.2 Global RNAi for Therapeutic Growth Trends by Region
2.2.1 Global RNAi for Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 RNAi for Therapeutic Historic Market Size by Region (2020-2025)
2.2.3 RNAi for Therapeutic Forecasted Market Size by Region (2026-2031)
2.3 RNAi for Therapeutic Market Dynamics
2.3.1 RNAi for Therapeutic Industry Trends
2.3.2 RNAi for Therapeutic Market Drivers
2.3.3 RNAi for Therapeutic Market Challenges
2.3.4 RNAi for Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNAi for Therapeutic Players by Revenue
3.1.1 Global Top RNAi for Therapeutic Players by Revenue (2020-2025)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2020-2025)
3.2 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by RNAi for Therapeutic Revenue
3.4 Global RNAi for Therapeutic Market Concentration Ratio
3.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2024
3.5 Global Key Players of RNAi for Therapeutic Head office and Area Served
3.6 Global Key Players of RNAi for Therapeutic, Product and Application
3.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 RNAi for Therapeutic Breakdown Data by Type
4.1 Global RNAi for Therapeutic Historic Market Size by Type (2020-2025)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031)
5 RNAi for Therapeutic Breakdown Data by Application
5.1 Global RNAi for Therapeutic Historic Market Size by Application (2020-2025)
5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America RNAi for Therapeutic Market Size (2020-2031)
6.2 North America RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America RNAi for Therapeutic Market Size by Country (2020-2025)
6.4 North America RNAi for Therapeutic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNAi for Therapeutic Market Size (2020-2031)
7.2 Europe RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe RNAi for Therapeutic Market Size by Country (2020-2025)
7.4 Europe RNAi for Therapeutic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNAi for Therapeutic Market Size (2020-2031)
8.2 Asia-Pacific RNAi for Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region (2020-2025)
8.4 Asia-Pacific RNAi for Therapeutic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNAi for Therapeutic Market Size (2020-2031)
9.2 Latin America RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America RNAi for Therapeutic Market Size by Country (2020-2025)
9.4 Latin America RNAi for Therapeutic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNAi for Therapeutic Market Size (2020-2031)
10.2 Middle East & Africa RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country (2020-2025)
10.4 Middle East & Africa RNAi for Therapeutic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Details
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Arbutus Biopharma (Tekmira)
11.2.1 Arbutus Biopharma (Tekmira) Company Details
11.2.2 Arbutus Biopharma (Tekmira) Business Overview
11.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
11.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025)
11.2.5 Arbutus Biopharma (Tekmira) Recent Development
11.3 Arrowhead
11.3.1 Arrowhead Company Details
11.3.2 Arrowhead Business Overview
11.3.3 Arrowhead RNAi for Therapeutic Introduction
11.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025)
11.3.5 Arrowhead Recent Development
11.4 Dicerna Pharmaceuticals
11.4.1 Dicerna Pharmaceuticals Company Details
11.4.2 Dicerna Pharmaceuticals Business Overview
11.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
11.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.4.5 Dicerna Pharmaceuticals Recent Development
11.5 Mirna Therapeutics
11.5.1 Mirna Therapeutics Company Details
11.5.2 Mirna Therapeutics Business Overview
11.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
11.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
11.5.5 Mirna Therapeutics Recent Development
11.6 Quark Pharmaceuticals
11.6.1 Quark Pharmaceuticals Company Details
11.6.2 Quark Pharmaceuticals Business Overview
11.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
11.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.6.5 Quark Pharmaceuticals Recent Development
11.7 RXi Pharmaceuticals
11.7.1 RXi Pharmaceuticals Company Details
11.7.2 RXi Pharmaceuticals Business Overview
11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
11.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.7.5 RXi Pharmaceuticals Recent Development
11.8 Silence Therapeutics
11.8.1 Silence Therapeutics Company Details
11.8.2 Silence Therapeutics Business Overview
11.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
11.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
11.8.5 Silence Therapeutics Recent Development
11.9 Benitec Biopharma
11.9.1 Benitec Biopharma Company Details
11.9.2 Benitec Biopharma Business Overview
11.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
11.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)
11.9.5 Benitec Biopharma Recent Development
11.10 miRagen Therapeutics
11.10.1 miRagen Therapeutics Company Details
11.10.2 miRagen Therapeutics Business Overview
11.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
11.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
11.10.5 miRagen Therapeutics Recent Development
11.11 Sylentis
11.11.1 Sylentis Company Details
11.11.2 Sylentis Business Overview
11.11.3 Sylentis RNAi for Therapeutic Introduction
11.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2020-2025)
11.11.5 Sylentis Recent Development
11.12 Gradalis
11.12.1 Gradalis Company Details
11.12.2 Gradalis Business Overview
11.12.3 Gradalis RNAi for Therapeutic Introduction
11.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2020-2025)
11.12.5 Gradalis Recent Development
11.13 Sirnaomics
11.13.1 Sirnaomics Company Details
11.13.2 Sirnaomics Business Overview
11.13.3 Sirnaomics RNAi for Therapeutic Introduction
11.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025)
11.13.5 Sirnaomics Recent Development
11.14 Silenseed
11.14.1 Silenseed Company Details
11.14.2 Silenseed Business Overview
11.14.3 Silenseed RNAi for Therapeutic Introduction
11.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2020-2025)
11.14.5 Silenseed Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global RNAi for Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi for Therapeutic Market Perspective (2020-2031)
2.2 Global RNAi for Therapeutic Growth Trends by Region
2.2.1 Global RNAi for Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 RNAi for Therapeutic Historic Market Size by Region (2020-2025)
2.2.3 RNAi for Therapeutic Forecasted Market Size by Region (2026-2031)
2.3 RNAi for Therapeutic Market Dynamics
2.3.1 RNAi for Therapeutic Industry Trends
2.3.2 RNAi for Therapeutic Market Drivers
2.3.3 RNAi for Therapeutic Market Challenges
2.3.4 RNAi for Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNAi for Therapeutic Players by Revenue
3.1.1 Global Top RNAi for Therapeutic Players by Revenue (2020-2025)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2020-2025)
3.2 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by RNAi for Therapeutic Revenue
3.4 Global RNAi for Therapeutic Market Concentration Ratio
3.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2024
3.5 Global Key Players of RNAi for Therapeutic Head office and Area Served
3.6 Global Key Players of RNAi for Therapeutic, Product and Application
3.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 RNAi for Therapeutic Breakdown Data by Type
4.1 Global RNAi for Therapeutic Historic Market Size by Type (2020-2025)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031)
5 RNAi for Therapeutic Breakdown Data by Application
5.1 Global RNAi for Therapeutic Historic Market Size by Application (2020-2025)
5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America RNAi for Therapeutic Market Size (2020-2031)
6.2 North America RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America RNAi for Therapeutic Market Size by Country (2020-2025)
6.4 North America RNAi for Therapeutic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNAi for Therapeutic Market Size (2020-2031)
7.2 Europe RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe RNAi for Therapeutic Market Size by Country (2020-2025)
7.4 Europe RNAi for Therapeutic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNAi for Therapeutic Market Size (2020-2031)
8.2 Asia-Pacific RNAi for Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region (2020-2025)
8.4 Asia-Pacific RNAi for Therapeutic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNAi for Therapeutic Market Size (2020-2031)
9.2 Latin America RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America RNAi for Therapeutic Market Size by Country (2020-2025)
9.4 Latin America RNAi for Therapeutic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNAi for Therapeutic Market Size (2020-2031)
10.2 Middle East & Africa RNAi for Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country (2020-2025)
10.4 Middle East & Africa RNAi for Therapeutic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Details
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Arbutus Biopharma (Tekmira)
11.2.1 Arbutus Biopharma (Tekmira) Company Details
11.2.2 Arbutus Biopharma (Tekmira) Business Overview
11.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
11.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025)
11.2.5 Arbutus Biopharma (Tekmira) Recent Development
11.3 Arrowhead
11.3.1 Arrowhead Company Details
11.3.2 Arrowhead Business Overview
11.3.3 Arrowhead RNAi for Therapeutic Introduction
11.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025)
11.3.5 Arrowhead Recent Development
11.4 Dicerna Pharmaceuticals
11.4.1 Dicerna Pharmaceuticals Company Details
11.4.2 Dicerna Pharmaceuticals Business Overview
11.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
11.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.4.5 Dicerna Pharmaceuticals Recent Development
11.5 Mirna Therapeutics
11.5.1 Mirna Therapeutics Company Details
11.5.2 Mirna Therapeutics Business Overview
11.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
11.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
11.5.5 Mirna Therapeutics Recent Development
11.6 Quark Pharmaceuticals
11.6.1 Quark Pharmaceuticals Company Details
11.6.2 Quark Pharmaceuticals Business Overview
11.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
11.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.6.5 Quark Pharmaceuticals Recent Development
11.7 RXi Pharmaceuticals
11.7.1 RXi Pharmaceuticals Company Details
11.7.2 RXi Pharmaceuticals Business Overview
11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
11.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
11.7.5 RXi Pharmaceuticals Recent Development
11.8 Silence Therapeutics
11.8.1 Silence Therapeutics Company Details
11.8.2 Silence Therapeutics Business Overview
11.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
11.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
11.8.5 Silence Therapeutics Recent Development
11.9 Benitec Biopharma
11.9.1 Benitec Biopharma Company Details
11.9.2 Benitec Biopharma Business Overview
11.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
11.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)
11.9.5 Benitec Biopharma Recent Development
11.10 miRagen Therapeutics
11.10.1 miRagen Therapeutics Company Details
11.10.2 miRagen Therapeutics Business Overview
11.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
11.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
11.10.5 miRagen Therapeutics Recent Development
11.11 Sylentis
11.11.1 Sylentis Company Details
11.11.2 Sylentis Business Overview
11.11.3 Sylentis RNAi for Therapeutic Introduction
11.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2020-2025)
11.11.5 Sylentis Recent Development
11.12 Gradalis
11.12.1 Gradalis Company Details
11.12.2 Gradalis Business Overview
11.12.3 Gradalis RNAi for Therapeutic Introduction
11.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2020-2025)
11.12.5 Gradalis Recent Development
11.13 Sirnaomics
11.13.1 Sirnaomics Company Details
11.13.2 Sirnaomics Business Overview
11.13.3 Sirnaomics RNAi for Therapeutic Introduction
11.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025)
11.13.5 Sirnaomics Recent Development
11.14 Silenseed
11.14.1 Silenseed Company Details
11.14.2 Silenseed Business Overview
11.14.3 Silenseed RNAi for Therapeutic Introduction
11.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2020-2025)
11.14.5 Silenseed Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of siRNA
Table 3. Key Players of miRNA
Table 4. Key Players of shRNA
Table 5. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global RNAi for Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global RNAi for Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global RNAi for Therapeutic Market Share by Region (2020-2025)
Table 9. Global RNAi for Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global RNAi for Therapeutic Market Share by Region (2026-2031)
Table 11. RNAi for Therapeutic Market Trends
Table 12. RNAi for Therapeutic Market Drivers
Table 13. RNAi for Therapeutic Market Challenges
Table 14. RNAi for Therapeutic Market Restraints
Table 15. Global RNAi for Therapeutic Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global RNAi for Therapeutic Market Share by Players (2020-2025)
Table 17. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Table 18. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served
Table 21. Global Key Players of RNAi for Therapeutic, Product and Application
Table 22. Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Table 26. Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global RNAi for Therapeutic Revenue Market Share by Type (2026-2031)
Table 28. Global RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Table 30. Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global RNAi for Therapeutic Revenue Market Share by Application (2026-2031)
Table 32. North America RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific RNAi for Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific RNAi for Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific RNAi for Therapeutic Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 47. Alnylam Pharmaceuticals Company Details
Table 48. Alnylam Pharmaceuticals Business Overview
Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 51. Alnylam Pharmaceuticals Recent Development
Table 52. Arbutus Biopharma (Tekmira) Company Details
Table 53. Arbutus Biopharma (Tekmira) Business Overview
Table 54. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 55. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 56. Arbutus Biopharma (Tekmira) Recent Development
Table 57. Arrowhead Company Details
Table 58. Arrowhead Business Overview
Table 59. Arrowhead RNAi for Therapeutic Product
Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 61. Arrowhead Recent Development
Table 62. Dicerna Pharmaceuticals Company Details
Table 63. Dicerna Pharmaceuticals Business Overview
Table 64. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 65. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 66. Dicerna Pharmaceuticals Recent Development
Table 67. Mirna Therapeutics Company Details
Table 68. Mirna Therapeutics Business Overview
Table 69. Mirna Therapeutics RNAi for Therapeutic Product
Table 70. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 71. Mirna Therapeutics Recent Development
Table 72. Quark Pharmaceuticals Company Details
Table 73. Quark Pharmaceuticals Business Overview
Table 74. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 75. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 76. Quark Pharmaceuticals Recent Development
Table 77. RXi Pharmaceuticals Company Details
Table 78. RXi Pharmaceuticals Business Overview
Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 81. RXi Pharmaceuticals Recent Development
Table 82. Silence Therapeutics Company Details
Table 83. Silence Therapeutics Business Overview
Table 84. Silence Therapeutics RNAi for Therapeutic Product
Table 85. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 86. Silence Therapeutics Recent Development
Table 87. Benitec Biopharma Company Details
Table 88. Benitec Biopharma Business Overview
Table 89. Benitec Biopharma RNAi for Therapeutic Product
Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 91. Benitec Biopharma Recent Development
Table 92. miRagen Therapeutics Company Details
Table 93. miRagen Therapeutics Business Overview
Table 94. miRagen Therapeutics RNAi for Therapeutic Product
Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 96. miRagen Therapeutics Recent Development
Table 97. Sylentis Company Details
Table 98. Sylentis Business Overview
Table 99. Sylentis RNAi for Therapeutic Product
Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 101. Sylentis Recent Development
Table 102. Gradalis Company Details
Table 103. Gradalis Business Overview
Table 104. Gradalis RNAi for Therapeutic Product
Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 106. Gradalis Recent Development
Table 107. Sirnaomics Company Details
Table 108. Sirnaomics Business Overview
Table 109. Sirnaomics RNAi for Therapeutic Product
Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 111. Sirnaomics Recent Development
Table 112. Silenseed Company Details
Table 113. Silenseed Business Overview
Table 114. Silenseed RNAi for Therapeutic Product
Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 116. Silenseed Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report
List of Figures
Figure 1. RNAi for Therapeutic Picture
Figure 2. Global RNAi for Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global RNAi for Therapeutic Market Share by Type: 2024 VS 2031
Figure 4. siRNA Features
Figure 5. miRNA Features
Figure 6. shRNA Features
Figure 7. Global RNAi for Therapeutic Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global RNAi for Therapeutic Market Share by Application: 2024 VS 2031
Figure 9. Cancer Case Studies
Figure 10. Cardiovascular Case Studies
Figure 11. HBV Case Studies
Figure 12. Others Case Studies
Figure 13. RNAi for Therapeutic Report Years Considered
Figure 14. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global RNAi for Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global RNAi for Therapeutic Market Share by Region: 2024 VS 2031
Figure 17. Global RNAi for Therapeutic Market Share by Players in 2024
Figure 18. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2024
Figure 20. North America RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 22. United States RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 26. Germany RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific RNAi for Therapeutic Market Share by Region (2020-2031)
Figure 34. China RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 42. Mexico RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 46. Turkey RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 50. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 51. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 52. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 53. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 54. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 55. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 56. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 57. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 58. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 59. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 60. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 61. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 62. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of siRNA
Table 3. Key Players of miRNA
Table 4. Key Players of shRNA
Table 5. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global RNAi for Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global RNAi for Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global RNAi for Therapeutic Market Share by Region (2020-2025)
Table 9. Global RNAi for Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global RNAi for Therapeutic Market Share by Region (2026-2031)
Table 11. RNAi for Therapeutic Market Trends
Table 12. RNAi for Therapeutic Market Drivers
Table 13. RNAi for Therapeutic Market Challenges
Table 14. RNAi for Therapeutic Market Restraints
Table 15. Global RNAi for Therapeutic Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global RNAi for Therapeutic Market Share by Players (2020-2025)
Table 17. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Table 18. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served
Table 21. Global Key Players of RNAi for Therapeutic, Product and Application
Table 22. Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Table 26. Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global RNAi for Therapeutic Revenue Market Share by Type (2026-2031)
Table 28. Global RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Table 30. Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global RNAi for Therapeutic Revenue Market Share by Application (2026-2031)
Table 32. North America RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific RNAi for Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific RNAi for Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific RNAi for Therapeutic Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa RNAi for Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa RNAi for Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa RNAi for Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 47. Alnylam Pharmaceuticals Company Details
Table 48. Alnylam Pharmaceuticals Business Overview
Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 51. Alnylam Pharmaceuticals Recent Development
Table 52. Arbutus Biopharma (Tekmira) Company Details
Table 53. Arbutus Biopharma (Tekmira) Business Overview
Table 54. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 55. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 56. Arbutus Biopharma (Tekmira) Recent Development
Table 57. Arrowhead Company Details
Table 58. Arrowhead Business Overview
Table 59. Arrowhead RNAi for Therapeutic Product
Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 61. Arrowhead Recent Development
Table 62. Dicerna Pharmaceuticals Company Details
Table 63. Dicerna Pharmaceuticals Business Overview
Table 64. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 65. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 66. Dicerna Pharmaceuticals Recent Development
Table 67. Mirna Therapeutics Company Details
Table 68. Mirna Therapeutics Business Overview
Table 69. Mirna Therapeutics RNAi for Therapeutic Product
Table 70. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 71. Mirna Therapeutics Recent Development
Table 72. Quark Pharmaceuticals Company Details
Table 73. Quark Pharmaceuticals Business Overview
Table 74. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 75. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 76. Quark Pharmaceuticals Recent Development
Table 77. RXi Pharmaceuticals Company Details
Table 78. RXi Pharmaceuticals Business Overview
Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 81. RXi Pharmaceuticals Recent Development
Table 82. Silence Therapeutics Company Details
Table 83. Silence Therapeutics Business Overview
Table 84. Silence Therapeutics RNAi for Therapeutic Product
Table 85. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 86. Silence Therapeutics Recent Development
Table 87. Benitec Biopharma Company Details
Table 88. Benitec Biopharma Business Overview
Table 89. Benitec Biopharma RNAi for Therapeutic Product
Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 91. Benitec Biopharma Recent Development
Table 92. miRagen Therapeutics Company Details
Table 93. miRagen Therapeutics Business Overview
Table 94. miRagen Therapeutics RNAi for Therapeutic Product
Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 96. miRagen Therapeutics Recent Development
Table 97. Sylentis Company Details
Table 98. Sylentis Business Overview
Table 99. Sylentis RNAi for Therapeutic Product
Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 101. Sylentis Recent Development
Table 102. Gradalis Company Details
Table 103. Gradalis Business Overview
Table 104. Gradalis RNAi for Therapeutic Product
Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 106. Gradalis Recent Development
Table 107. Sirnaomics Company Details
Table 108. Sirnaomics Business Overview
Table 109. Sirnaomics RNAi for Therapeutic Product
Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 111. Sirnaomics Recent Development
Table 112. Silenseed Company Details
Table 113. Silenseed Business Overview
Table 114. Silenseed RNAi for Therapeutic Product
Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 116. Silenseed Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report
List of Figures
Figure 1. RNAi for Therapeutic Picture
Figure 2. Global RNAi for Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global RNAi for Therapeutic Market Share by Type: 2024 VS 2031
Figure 4. siRNA Features
Figure 5. miRNA Features
Figure 6. shRNA Features
Figure 7. Global RNAi for Therapeutic Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global RNAi for Therapeutic Market Share by Application: 2024 VS 2031
Figure 9. Cancer Case Studies
Figure 10. Cardiovascular Case Studies
Figure 11. HBV Case Studies
Figure 12. Others Case Studies
Figure 13. RNAi for Therapeutic Report Years Considered
Figure 14. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global RNAi for Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global RNAi for Therapeutic Market Share by Region: 2024 VS 2031
Figure 17. Global RNAi for Therapeutic Market Share by Players in 2024
Figure 18. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2024
Figure 20. North America RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 22. United States RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 26. Germany RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific RNAi for Therapeutic Market Share by Region (2020-2031)
Figure 34. China RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 42. Mexico RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa RNAi for Therapeutic Market Share by Country (2020-2031)
Figure 46. Turkey RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE RNAi for Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 50. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 51. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 52. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 53. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 54. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 55. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 56. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 57. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 58. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 59. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 60. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 61. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 62. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232